Ambu A/S

TRANSACTIONS UNDER AMBU’S SHARE BUYBACK PROGRAM

14.9.2026 10:10:17 CEST | Ambu A/S | Changes in company's own shares

On 6 May 2026, Ambu announced a share buyback program (company announcement no. 12 2025/26). The share buyback program is carried out in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) (as amended) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016, also referred to as the Safe Harbor Regulations.                                                                                              

During the program, Ambu will repurchase shares for a total amount of up to DKK 300m from 6 May 2026 until no later than 30 September 2026. The repurchased shares are bought with the aim of completing a share capital decrease as set out in Article 5(2)(a) in MAR.  

The following transactions have been made under the program from 07 Sept 2026 to 11 Sept 2026: 

  

Number of shares 

Average purchase price, DKK 

Transaction value, DKK 

Accumulated under the program after last announcement 

4,098,739 

66.8507 

274,003,673 

2026.09.07 

20,000 

67.6566 

1,353,132 

2026.09.08 

125,000 

66.9486 

8,368,572 

2026.09.09 

14,000 

65.5421 

917,589 

2026.09.10 

5,000 

66.0320 

330,160 

2026.09.11 

23,000 

65.5779 

1,508,291 

Accumulated under the program 

4,285,739 

66.8453 

286,481,417 

After the above disclosed transactions DKK 13,518,583 remains to be repurchased. Ambu now owns 8,435,350 treasury shares, corresponding to 3.1% of the share capital.

Contacts

Tine Bjørn Schmidt

Director of Corporate Communications

tisc@ambu.com

Lisa Bedell Clive

Head of Investor Relations

licl@ambu.com

About Ambu A/S

Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.

Attachments

Subscribe to our company announcements

Keep up to date with our company announcements by subscribing.

Visit our pressroom and see more company announcements from us.

Our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye